Form 4: Verastem CEO Dan Paterson Reports Stock Sales and RSU Grant

Verastem's CEO, Dan Paterson, reported selling shares to cover withholding requirements and receiving a grant of restricted stock units (RSUs).

Summary

• On June 17, 2024, Dan Paterson, the President and CEO of Verastem, Inc., sold 244 shares of common stock at $3.49 per share to satisfy statutory withholding requirements related to vesting restricted stock units.
• On June 18, 2024, Paterson was granted 150,000 restricted stock units (RSUs) under the company's Amended and Restated 2021 Equity Incentive Plan.
• These RSUs vest in three equal installments on the first three anniversaries of the grant date (June 18, 2024), contingent upon continued service to the company, and will be fully vested by June 18, 2027.
• On June 20, 2024, Paterson sold 183 shares of common stock at $3.21 per share to satisfy statutory withholding requirements related to vesting restricted stock units.
• Following these transactions, Paterson directly owns 236,063 shares of Verastem common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The RSU grant indicates confidence in the company's future, while the stock sales are routine and related to tax obligations.

Positives

• The grant of 150,000 RSUs to the CEO aligns his interests with the long-term performance of the company.
• The vesting schedule of the RSUs incentivizes continued service and commitment from the CEO over the next three years.

Future Outlook

The CEO's RSU grant vests over three years, incentivizing long-term performance and continued service to the company.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions in the company's stock. RSU grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Executive compensation packages, including RSU grants, are common in the biotech industry to align management's interests with shareholder value.
• Vesting schedules of three years are typical for RSU grants to ensure long-term commitment.
• Comparable companies like Blueprint Medicines or Relay Therapeutics also utilize equity-based compensation for their executives.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning management's interests with long-term company performance.
• Employees may see the CEO's continued commitment as a positive indicator of company stability.

Key Dates